Login to Your Account

ODAC Looks at Sample Audit to Lighten Load of PFS Trials

By Mari Serebrov
Washington Editor

Wednesday, July 25, 2012

Forget whether progression-free survival (PFS) should be a surrogate endpoint in cancer trials, the FDA said as it charged the Oncologic Drug Advisory Committee (ODAC) Tuesday to look at reducing the central review audit burden as a way to streamline cancer trials.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription